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Objective: To provide guidance about management of psoriatic disease during the COVID-19 139 
pandemic. 140 
 141 
Study Design: A task force (TF) of 18 physician voting members with expertise in dermatology, 142 
rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was 143 
supplemented by non-voting members which included fellows and National Psoriasis Foundation 144 
(NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by 145 
questions received by the NPF. A Delphi process was conducted.  146 
 147 
Results: The TF approved 22 guidance statements. The average of the votes was within the category 148 
of agreement for all statements. All guidance statements proposed were recommended, 9 with high 149 
consensus, 13 with moderate consensus. 150 
  151 
Limitations: The evidence behind many guidance statements is limited in quality. 152 
 153 
Conclusion: These statements provide guidance for the management of patients with psoriatic 154 
disease on topics ranging from how the disease and its treatments impact COVID-19 risk and 155 





their risk of getting infected with SARS-CoV-2 and what they should do if they develop COVID-19. 157 
The guidance is intended to be a living document that will be updated by the TF as data emerge.  158 
 159 
 160 
Capsule Summary: 161 
 162 
• The NPF COVID-19 Task Force produced 22 guidance statements to promote optimal 163 
management of psoriatic disease during the pandemic.  164 
• Shared decision making is recommended as is adherence to evidence-based 165 
recommendations when available. The guidance statements will be updated when necessary 166 







Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2), a single stranded RNA virus that binds to 170 
the ACE-2 receptor and causes illness called COVID-19, has precipitated devastating personal, 171 
economic and societal repercussions worldwide.1-4 SARS-CoV-2 usually causes a mild, self-limited 172 
illness, but about 15% of affected individuals have a more severe, sometimes life-threatening course, 173 
with the risk of poor outcomes increasing with age and comorbidities.5-7 Diffuse alveolar damage and 174 
acute respiratory distress syndrome are the most common presentations in severe COVID-19. 175 
Additionally, thrombo-embolic events along with direct and indirect viral-induced injury may target the 176 
skin, gastrointestinal tract, kidney, heart and brain with devastating consequences.8-10 177 
 178 
The type 1 interferon response, required to clear the virus, is often insufficient in the early phase of 179 
SARS-CoV-2 infection but a delayed persistent elevation may develop as the illness progresses.11 180 
Profound dysregulation of innate and acquired immunity can occur with more severe COVID-19, 181 
including significant lymphopenia as a direct result of viral-induced apoptosis and necrosis of 182 
lymphocytes in the spleen and lymph nodes.12  The persistent interferon response can result in 183 
systemic hyperinflammation (a.k.a., cytokine storm).13, 14 Several of the cytokines elevated in severe 184 
COVID-19 patients (TNF, IL-6, and IL-17) are also elevated in patients with psoriatic disease.15-17 185 
 186 
The current model of COVID-19 is that immune suppression in early infection may be harmful by 187 
allowing uncontrolled SARS-CoV-2 replication and dissemination, but may be helpful in severe illness 188 





psoriatic disease directly or indirectly impact immune pathways involved in COVID-19.19-22 Patients 190 
and providers are concerned about the safety of immunomodulating agents in the setting of the 191 
COVID-19 pandemic. These concerns are particularly relevant given that many of the comorbidities 192 
associated with psoriasis and psoriatic arthritis (PsA), including obesity, diabetes and cardiovascular 193 
disease, are risk factors for the development of severe COVID-19.23, 24 To address the questions 194 
posed by patients and providers, the National Psoriasis Foundation (NPF) commissioned a COVID-195 
19 task force (TF) to develop scientifically-based guidance that promotes optimal management of 196 
psoriatic disease during the pandemic.  197 






See online supplement for detailed methods.  200 
 201 
Establishment of Task Force 202 
The COVID-19 TF includes 18 physicians with a variety of expertise relevant to decision-making in 203 
the pandemic from different geographical areas within the United States and Canada, many of whom 204 
have frontline experience managing a surge of COVID-19 patients (E Table 1). The TF was 205 
supplemented by non-voting members which include 4 trainees in dermatology, rheumatology, and 206 
infectious diseases, 1 post-doctoral fellow in epidemiology, as well as senior staff from the NPF.  207 
 208 
Evidence Synthesis  209 
The TF co-chairs completed weekly literature searches for COVID-19 in relation to psoriatic disease. 210 
TF members also recommended papers of broad importance to COVID-19 related to its basic 211 
biology, epidemiology, and treatment. Additional sources of data were obtained from the CDC, WHO, 212 
FDA, and NIH.  213 
 214 
Development of Clinical Questions 215 
The TF met every 2 weeks to discuss the developments in the literature and clinical experience. 216 
Clinical questions relevant to the psoriatic disease community were iterated and informed by 217 
questions received by the NPF from the broader patient and clinical community. The questions were 218 





of the TF convened to draft responses to the clinical questions based on the available evidence. 220 
These responses were reviewed and drafted into guidance statements.  221 
 222 
Modified Delphi Process 223 
The guidance statements were presented to the 18 TF members using a modified Delphi process 224 
including 2 rounds of voting with discussion in between. The Delphi approach was based on the 225 
RAND appropriateness method, which has been extensively validated.25-31  226 
 227 
TF members were asked to report their level of agreement anonymously with each guidance 228 
statement on a scale of 1-9. A rating of 1 corresponded to “complete disagreement,” 5 corresponded 229 
to “uncertain or neutral,” and 9 corresponded to “complete agreement.” The members were able to 230 
provide anonymous written comments.  Median vote ratings of 1–3, 4–6, and 7–9 were defined a 231 
priori as disagreement, uncertainty/neutral, and agreement, respectively. Panel consensus was 232 
determined to be “low” when ≥5 votes fell into the 1–3 rating range with ≥5 votes concurrently falling 233 
into the 7–9 rating range. Consensus was interpreted as “high” if all 18 votes fell within a single tertile, 234 
with all other combinations considered as “moderate” levels of consensus. The results were analyzed 235 
by the NPF with an independent analysis of the data by a non-voting member of the TF, which 236 












The TF Delphi was completed over a 2 week period (E Table 2). Five categories of questions were 245 
explored (E Table 3) with 100% complete voting on 22 guidance statements (Table 4 & E-Table 4). 246 
The median was within the category of agreement for all statements, with the number of votes outside 247 
the range of agreement being only 1 or 2 for statements where agreement was not unanimous. All 248 
guidance statements were recommended, 9 with high consensus, and the remainder with moderate 249 
consensus. 250 
 251 
Category 1: What are the effects of psoriatic disease itself on SARS-CoV-2 infection and COVID-19 252 
illness? 253 
 254 
Patients with psoriatic disease appear to have similar rates of infection with SARS-CoV-2 and 255 
COVID-19 outcomes32-36 as the general population (Guidance 1.1). However, uncertainty remains 256 
regarding this question. First, a few reports suggest that psoriasis patients may be more prone to 257 
infection with COVID-19 or have worse outcomes.37-39  For example, a United Kingdom study with 258 
over 17 million patients found a small but statistically increased risk of death from COVID-19 (fully 259 
adjusted Hazards Ratio (HR) 1.19 [95% CI 1.11-1.27]) in individuals with either psoriasis, rheumatoid 260 
arthritis or lupus.38  It is unknown from this study the degree to which the observed finding is driven by 261 





thrombotic complications that can also occur in COVID-19.40-54 There was unanimous agreement that 263 
severity of COVID-19 is driven by risk factors such as older age and comorbidities (Guidance 1.2). 32, 264 
35, 36, 38, 55-58 Psoriatic disease—particularly severe psoriasis— is associated with many of the 265 
comorbidities that drive COVID-19 mortality.44, 48, 59 266 
 267 
Category 2: What are the effects of psoriasis or psoriatic arthritis treatment on SARS-CoV-2 infection 268 
and COVID-19 illness? 269 
 270 
The existing literature suggests that treatments for psoriasis and/or PsA do not meaningfully alter the 271 
risk of acquiring SARS-CoV-2 infection or having worse COVID-19 outcomes (Guidance  2.1) 36, 60-86.  272 
Cyclosporine, the most broadly immunosuppressive of psoriasis treatments, was not found to alter 273 
risk of COVID-19 in 130 patients in Italy with psoriasis or atopic dermatitis (2 became infected with 274 
SARS-CoV-2 and recovered without hospitalization).70 This study lacked a comparison group and is 275 
too small to reach definitive conclusions. One study suggested that psoriasis patients on biologics 276 
were more likely to be hospitalized for COVID-19 but did not adjust for risk factors known to drive 277 
poor COVID19 outcomes.87 278 
 279 
The rheumatology literature also suggests that treatments used for psoriatic disease (such as TNF 280 
inhibitors and methotrexate) do not negatively impact COVID-1988-91 with one large registry (600 case 281 
reports from 40 countries) finding that TNF inhibitors are associated with a reduced adjusted odds of 282 
COVID-19 hospitalization compared to patients with rheumatic conditions not treated with TNF 283 





registries of IBD patients.92, 93 Small case series have reported poor COVID-19 outcomes in patients 285 
on JAK inhibitors for PsA94 and secukinumab for ankylosing spondylitis; 90 however, these isolated 286 
reports could be due to selection bias, chance, or underlying comorbidity. By contrast, an analysis of 287 
about 1400 patients from the rheumatology, gastroenterology, and dermatology literature concluded 288 
that biologic or targeted synthetic disease-modifying antirheumatic drug therapy has not been 289 
associated with more severe COVID-19 outcomes.32  290 
 291 
Given these data, patients who are not infected with SARS-CoV-2 should continue their biologic or 292 
oral therapies for psoriasis and/or psoriatic arthritis in most cases (Guidance 2.2). Nevertheless, the 293 
existing literature is largely based on small case series or large registries of spontaneous reports and 294 
therefore shared decision-making between clinician and patient is recommended (Guidance 2.2, 2.4, 295 
2.5). By contrast, studies in the rheumatology and gastroenterology literature have observed that 296 
chronic use of oral corticosteroids is associated with worse COVID-19 outcomes (i.e., hospitalization, 297 
or a composite outcome of  ICU admission, ventilator use, and/or death).32, 91, 92 Chronic systemic 298 
corticosteroids should be avoided, if possible, for the management of psoriatic arthritis (guidance 299 
2.3)95. 300 
 301 
Category 3: How should medical care be delivered to patients with psoriatic disease to lower their 302 
risk of infection with SARS-CoV-2 while still ensuring quality of care? 303 
 304 
The pandemic has disrupted the ability of patients and providers ability to meet in person due to 305 





transmission, and patients’ personal and economic hardships.96-99 Patients express concern about 307 
being exposed to SARS-CoV-2 in the clinical setting either directly or indirectly (i.e., on public 308 
transportation). Telemedicine can achieve similar outcomes for psoriasis patients compared to in 309 
person care with a dermatologist;100-102 however, limited information available on management of  310 
psoriatic arthritis with telemedicine.103, 104 Telemedicine should be considered when pandemic 311 
conditions limit in-person visits (Guidance 3.1).105 However, there are limitations of telemedicine, and 312 
therefore some patients should be evaluated in person (Guidance 3.2). Office-based phototherapy 313 
remains an important option for patients with psoriasis (Guidance 3.3, Table 5).106, 107 314 
 315 
Category 4: What should patients with psoriatic disease do to protect themselves from becoming 316 
infected with SARS-CoV-2? 317 
 318 
Patients should be advised to follow measures that prevent infection with SARS-CoV-2 (Guidance 319 
4.1, E-Table 6)108. These prevention measures should be followed at work (Guidance 4.2) and school 320 
(Guidance 4.3). In cases where measures to prevent transmission of SARS-CoV-2 at work or school 321 
cannot be maintained, shared decision-making is recommended to determine if specific 322 
accommodations are medically necessary (Guidance 4.2 and 4.3).  Psoriasis, even when involving 323 
the face or hands, is not a contraindication to face coverings and hand washing respectively, and a 324 
variety of approaches can be applied to mitigate skin irritation (E-Table 7).109-111 Patients with 325 
psoriatic disease should receive the seasonal inactivated (e.g. killed) influenza vaccine, which is of 326 





Providers may consider temporary discontinuation of methotrexate for 2 weeks after flu immunization 328 
in order to improve the immunogenicity of seasonal influenza vaccine.112 329 
 330 
Category 5: What should patients with psoriatic disease do if they become infected with SARS-CoV-331 
2? 332 
 333 
Patients with psoriatic disease who become infected with SARS-CoV-2 should monitor their 334 
symptoms (E-Table 8), discuss management of their psoriatic disease treatments with their health 335 
care providers, and should be prescribed and adhere to evidence-based COVID-19 treatments, if 336 
available (Guidance 5.1, 5.2). 86 113-115 The mortality benefit of initiation of corticosteroids in patients 337 
with severe COVID-19 outweighs the risks of potentially precipitating a psoriasis flare, and therefore, 338 
acute systemic corticosteroids are not contraindicated for the management of COVID-19 in patients 339 
with psoriatic disease (Guidance 5.3).115-117 Based on limited available data, and to be consistent with 340 
prescribing information, it may be prudent to hold treatments that target the immune system in the 341 
setting of suspected or confirmed SARS-CoV-2 infection, but the final decision needs to be 342 
determined on a case by case basis. Consistent with guidance from the FDA and the American 343 
College of Physicians, the use of hydroxychloroquine or chloroquine is not recommended to prevent 344 
or treat COVID-19 in patients with psoriatic disease outside of a clinical trial (guidance 5.4). 118-130 345 
Patients with psoriatic disease should be aware that infection with SARS-CoV-2 may result in a flare 346 
of psoriasis, which may occur due to discontinuation of psoriasis treatments, treatment of COVID-19 347 
with anti-malarial drugs, or due to triggering of inflammation as part of COVID-19 illness (Guidance 348 






Patients with psoriatic disease who become infected with SARS-CoV-2 should follow CDC guidance 351 
134-137 on home isolation and discuss with their healthcare providers when they can end home 352 
quarantine (Guidance 5.7, E-Table 9).116, 134, 138 139 In the event someone with psoriatic disease has 353 
close contact (E-Table 10) with an individual with suspected or confirmed SARS-CoV-2 infection, they 354 
should quarantine for 14 days after the last contact, as per CDC guidelines (guidance 5.8)140. The 355 
decision regarding continuing or holding psoriasis treatments during a period of quarantine should be 356 
individualized on a case-by-case basis between patient and provider. 357 
 358 
Resumption of psoriasis and/or psoriatic arthritis treatments held during SARS-CoV-2 infection should 359 
be decided on a case-by-case basis (guidance 5.5). The persistence of one or more symptoms of 360 
COVID-19, such as fatigue or joint pain, beyond the acute phase of the illness can occur141, and may 361 
complicate the decision to restart psoriasis or PsA medications. Therefore shared decision-making is 362 















The NPF COVID19 TF guidance statements serve to promote optimal management of psoriatic 374 
disease during the pandemic. There are several strengths to the approach taken. First, the TF 375 
assembled is a geographically diverse team with expertise in adult and pediatric dermatology, 376 
rheumatology, critical care, infectious diseases, epidemiology, and basic and translational 377 
immunology with experience managing surges in COVID-19.  The TF also includes trainees in 378 
dermatology, rheumatology and infectious disease who are on the frontlines managing COVID-19 379 
patients as well as senior staff from the NPF who are in touch daily with patients and providers 380 
worldwide whose questions are brought to the TF.  Second, we have established a robust process for 381 
staying up to date with the latest literature relevant to COVID-19 and the management of psoriatic 382 
disease resulting in the dissemination and evaluation of hundreds of peer reviewed publications by 383 
the TF. Third, a validated Delphi approach enabled transparency and reproducibility of our process 384 
for evaluating consensus statements.25-31  385 
 386 
Several limitations are acknowledged. First, the TF did not formally grade the strength of our 387 
recommendations.142 With the exception of guidance statements 4.4, 5.2, and 5.4, which are based 388 
on large scale randomized controlled trials, the evidence behind many of the guidance statements 389 
was often limited in quality.  For example, studies evaluating the safety of treatments for psoriasis and 390 
psoriatic arthritis in the setting of COVID-19 involve small case series or large collections of case 391 





studies, with appropriate comparator groups, adjustment for relevant confounding variables, and 393 
complete ascertainment of clinically important COVID-19 outcomes are urgently needed. Second, the 394 
guidance is not intended to be proscriptive nor comprehensive. The ultimate judgment regarding how 395 
these recommendations should be followed is best left with the treating clinician and the patient in 396 
light of the circumstances presented by the individual patient, and the variability and biological 397 
behavior of the disease and therapeutics. Third, the TF does not have global representation of 398 
experts or direct inclusion of patients.  399 
 400 
The guidance statements are intended to be part of a “living” document that will be updated and 401 
amended when necessary by the rapidly evolving science of COVID-19. Readers are encouraged to 402 
visit https://www.psoriasis.org/covid-19-resource-center regularly for the latest guidance from the TF 403 













Guidance Statement  Level of 
Consensus  
1.1 It is not known with certainty if having psoriatic disease meaningfully alters the risks 
of contracting SARS-CoV-2 (the virus that causes COVID-19 illness) or having a 
worse course of COVID-19 illness.  Existing data, with some exceptions, generally 
suggest that patients with psoriasis and/or psoriatic arthritis have similar rates of 
SARS-CoV-2 infection and COVID-19 outcomes as the general population. 
Moderate 
1.2 The likelihood of poor outcomes from COVID-19 is driven by risk factors such as 
older age and comorbidities such as chronic heart, lung, or kidney disease and 
metabolic disorders such as diabetes and obesity. Patients with psoriatic disease are 
more prone to these comorbidities, particularly in those with more severe disease.   
High 
2.1 It is not known with certainty if treatments for psoriasis and/or psoriatic arthritis 
meaningfully alter the risks of contracting SARS-CoV-2 (the virus that causes COVID-
19 illness) or having a worse course of COVID-19 illness.  Existing data generally 
suggest that treatments for psoriasis and/or psoriatic arthritis do not meaningfully 
alter the risk of acquiring SARS-CoV-2 infection or having worse COVID-19 
outcomes.   
Moderate 
2.2 It is recommended that patients who are not infected with SARS-CoV-2 continue their 
biologic or oral therapies for psoriasis and/or psoriatic arthritis in most cases. Shared 
decision-making between clinician and patient is recommended to guide discussions 
about use of systemic therapies during the pandemic (see guidance 2.5 for definition 
of shared decision making). 
High 
2.3 Chronic systemic corticosteroids should be avoided if possible for the management of 
psoriatic arthritis. If patients require chronic systemic corticosteroids for management 
of psoriatic arthritis, the dose should be tapered to the lowest dose necessary to 
achieve the desired therapeutic effect. Chronic systemic corticosteroid use for the 
treatment of psoriatic disease at the time of acute infection with SARS-CoV-2 may be 
associated with worse outcomes from COVID19 illness.  It is important to note, 
however, that corticosteroids may improve outcomes for COVID19 when initiated in 
hospitalized patients requiring oxygen treatment. 
High 
2.4 Individuals newly diagnosed with psoriasis and/or psoriatic arthritis or who are 
currently not receiving treatment should be aware that untreated psoriatic disease is 
associated with serious impact on physical and emotional health, and in the case of 
psoriatic arthritis, can lead to permanent joint damage and disability. Shared decision 
making between clinician and patient is recommended to guide discussions about 
use of systemic therapies during the pandemic (see guidance 2.5 for shared decision 
making).  
High 
2.5 Providers recommend shared decision making with patients. Shared decision making 
between clinician and patient should be guided by several factors, including the 
potential benefits of treatment, the activity of skin and/or joint disease and response 
to previous therapies, as well as the patient’s underlying risk for poor COVID19 
outcomes, and ability to maintain measures to prevent infection with SARS-CoV-2 






pandemic conditions. A review of known benefits of treatment accompanied by 
acknowledgment of the uncertainty related to the COVID19 pandemic and a 
discussion of a patient’s individual circumstances and preferences should guide 
decision making. 
3.1 Telemedicine should be offered to manage patients wherever possible when local 
restrictions or pandemic conditions limit the ability for in-person visits. The following 
patients can be managed with telemedicine: Patients who are clinically stable and 
previously started on psoriatic disease treatment. Patients requiring a follow-up visit 
and refills for medication. New patients without timely access to in-person visits. 
Patients diagnosed with COVID-19 who are experiencing a significant flare. If 
telemedicine visits become inadequate to monitor patients’ disease progress or 
manage new or evolving symptoms or signs of skin and joint disease, clinicians and 
patients should consider in-person visits. 
Moderate 
3.2 The following patients should be considered for in-person care if pandemic conditions 
allow (i.e., the clinical practice is open to see patients in person): Patients at risk for 
melanoma and non-melanoma skin cancer should be seen in person at a frequency 
consistent with standard of care for a full skin examination. New patients establishing 
care. Patients experiencing unstable psoriatic disease/flares. Patients requiring a 
thorough skin/or joint examination and a full physical examination for rheumatology 
patients. 
Moderate 
3.3 Providers recommend the recent guidelines published by Lim et al  on how to 
optimize safety of office phototherapy for the patients and staff in the setting of the 
pandemic. See Table 5 for details.  
High 
4.1 Patients should be advised to follow measures that prevent infection with SARS-CoV-
2. These preventative measures include: To practice good hand hygiene, to maintain 
physical distancing from non-household members, and to wear a face covering of the 
nose and mouth when indoors (except in their own home), and when outdoors, but 
unable to maintain physical distancing. Face coverings should not be used in children 
under 2 years old due to risk of suffocation. See E Table 6 for details. 
High 
4.2 Patients with psoriatic disease should follow measures to prevent infection with 
SARS-CoV-2 in the workplace. If the work place environment does not allow for 
maintenance of prevention measures, a shared decision-making process between the 
patient and his/her clinician is recommended to determine if specific accommodations 
are medically necessary, especially for individuals whom, due to age or underlying 
health conditions, are at especially high risk for poor COVID19 outcomes.  
Moderate 
4.3 Youth with psoriatic disease should follow measures to prevent infection with SARS-
CoV-2 while at school. These measures include maintaining 6 feet of physical 
distancing, consistently wearing masks if  over the age of 2 years, and washing 
hands frequently. If the school environment is unable to ensure these prevention 
measures or families believe their child may not be able to adhere to these practices, 
we encourage discussion with the patient, caregivers, and his/her clinician to 
collectively develop a learning plan in the best interest and safety of the child. 
High 
4.4. Patients with psoriatic disease should receive the seasonal inactivated (e.g. killed) 
influenza vaccine  when it becomes available. While this vaccine will not protect 
against SARS-CoV-2, influenza vaccine lowers the risk of infection from seasonal 






COVID-19 pandemic. Patients taking systemic medications for psoriasis or psoriatic  
arthritis should discuss the timing of influenza vaccination with respect to their 
systemic psoriatic medications with their health care provider in order to optimize the 
response to the influenza vaccine.  
5.1 Patients with psoriatic disease who become infected with SARS-CoV-2 should 
monitor their symptoms and discuss the management of their treatments with their 
health care providers. 
Moderate 
5.2 Patients with psoriatic disease who become infected with SARS-CoV-2 should be 
prescribed and adhere to evidence-based COVID-19 therapies.  Evidence-based 
therapies should be used, currently including supportive care for patients with mild 
disease, as well as dexamethasone (systemic corticosteroids) and remdesivir 
treatment, if available, for hospitalized patients requiring supplemental oxygen. The 
care of the hospitalized patient should include consultation with rheumatologists, 
dermatologists, and/or infectious disease specialists as medically necessary. 
Moderate 
5.3 Systemic corticosteroids for the management of COVID-19 in patients with psoriatic 
disease are not contraindicated and should not be withheld due to the concern of 
potentially flaring psoriasis upon withdrawal of corticosteroids when evidence 
demonstrates the effectiveness for treating COVID-19 illness. 
Moderate 
5.4 Hydroxychloroquine or chloroquine are not recommended for the prevention or 
treatment of COVID-19 in patients with psoriatic disease outside of a clinical trial. 
Cases of psoriasis flare have been reported in patients on anti-malarial medications, 
but the clinical significance is not well understood.  
High 
5.5 Resumption of psoriasis and/or psoriatic arthritis treatments held during SARS-CoV-2 
infection should be decided on a case-by-case basis. Most patients can restart 
psoriasis and/or psoriatic arthritis treatments after complete resolution of COVID-19 
symptoms. In those who have had a severe hospital course, shared decision making 
made on a case-by-case basis is recommended. 
Moderate 
5.6 Patients with psoriatic disease should be aware that infection with SARS-CoV-2 may 
result in a flare of psoriasis based on case reports. The clinical significance of the risk 
of COVID-19 flaring psoriasis is not known. 
Moderate 
5.7 Patients with psoriatic disease who become infected with SARS-CoV-2 should follow 
CDC guidance on home isolation and discuss with their healthcare providers when 
they can end home isolation. We recommend waiting a minimum of 10 days after 
COVID-19 symptom onset, along with fever resolution for 24 hours without 
antipyretics and improvement in other symptoms, before ending home isolation and 
returning to work, as patients are unlikely to be infectious after this point. In patients 
with severe cases of COVID-19 or when psoriasis patients are on medications with 
immunosuppressive effects, we recommend a case-by-case approach to determining 
the length of home isolation. 
Moderate 
5.8 Patients with close contact to someone with SARS-CoV-2 infection should quarantine 
themselves for 14 days after the last contact and discuss the management of their 
psoriatic disease treatment with their medical provider(s). 
Moderate 






Table 5: Methods to Reduce Risk of SARS-CoV-2 Transmission During Delivery of Office-Based Phototherapy 415 
 416 
Patient Protocol Staff Protocol 
• Screened for signs and symptoms of 
COVID-19 before entering the unit, 
understanding that treatment will be 
denied to symptomatic patients. 
• Attend the phototherapy appointment 
alone. Minors can be accompanied by a 
guardian, given all safety protocols are 
observed 
• Apply hand sanitizer upon entering and 
leaving the unit.  
• Patient provided with goggles, must 
sanitize them thoroughly, according to 
manufacturer's instruction 
• Wear a mask, unless phototherapy 
treatment of the face is required 
• Practice physical distancing 
 
• Schedule patients approximately 30 minutes apart 
per booth 
• Practice physical distancing, particularly in waiting 
area, with seats 6 feet apart. 
• Wear a mask, eye protection, and apply hand 
sanitizer before and after each patient encounter. 
• Avoid turning on the fan of the phototherapy unit if 
possible; if need be, treatment can be fractionated 
to avoid excessive heat build-up in the unit 
• Disinfect high-touch surfaces in the changing area 
after each patient 
• Disinfect high-touch area of the phototherapy 
equipment in between patients 
• Provide patients with disposable bags to store 
personal items 
• Provide goggles to patients if need be; ensuring 













Abbreviations and Acronyms 419 
• SARS COV-2 : Severe Acute Respiratory Coronavirus 2 420 
• COVID-19: Coronavirus disease 2019 421 
• IL: InterLeukin 422 
• TNF: Tumor Necrosis Factor 423 
• PsA: Psoriatic Arthritis 424 
• TF: Task Force 425 
• NPF: National Psoriasis Foundation 426 
• IBD: Inflammatory Bowel Disease 427 
• CDC: Centers for Disease Control 428 
• WHO: World Health Organization 429 
• FDA: Food and Drug Administration 430 
• NIH: National Institutes of Health 431 
• HR: Hazards Ratio 432 
• JAK inhibitor: Janus Kinase Inhibitor 433 
• SD: Standard Deviation 434 
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• The NPF COVID-19 Task Force produced 22 guidance statements to promote 
optimal management of psoriatic disease during the pandemic.  
• Shared decision making is recommended as is adherence to evidence-based 
recommendations when available. The guidance statements will be updated 
when necessary in accordance with rapidly evolving science of COVID-19. 
